A new trading day began on Friday, with Beam Therapeutics Inc (NASDAQ: BEAM) stock price up 7.79% from the previous day of trading, before settling in for the closing price of $24.40. BEAM’s price has ranged from $16.95 to $49.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 43297.50% over the last five years. Meanwhile, its annual earnings per share averaged -173.05%. With a float of $71.60 million, this company’s outstanding shares have now reached $81.63 million.
The firm has a total of 436 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.24%, operating margin of -52.31%, and the pretax margin is -40.16%.
Beam Therapeutics Inc (BEAM) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 13.15%, while institutional ownership is 81.40%. The most recent insider transaction that took place on Jul 02 ’24, was worth 17,167. In this transaction Chief Medical Officer of this company sold 748 shares at a rate of $22.95, taking the stock ownership to the 68,805 shares. Before that another transaction happened on Jul 01 ’24, when Company’s Chief Medical Officer sold 502 for $23.76, making the entire transaction worth $11,928. This insider now owns 69,553 shares in total.
Beam Therapeutics Inc (BEAM) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -173.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Here are Beam Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -4.66 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Analysing the last 5-days average volume posted by the [Beam Therapeutics Inc, BEAM], we can find that recorded value of 0.62 million was lower than the volume posted last year of 1.28 million. As of the previous 9 days, the stock’s Stochastic %D was 44.51%. Additionally, its Average True Range was 1.41.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 41.21%, which indicates a significant decrease from 69.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.66% in the past 14 days, which was lower than the 61.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.15, while its 200-day Moving Average is $27.39. Now, the first resistance to watch is $26.85. This is followed by the second major resistance level at $27.41. The third major resistance level sits at $28.48. If the price goes on to break the first support level at $25.23, it is likely to go to the next support level at $24.16. Now, if the price goes above the second support level, the third support stands at $23.60.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
With a market capitalization of 2.17 billion, the company has a total of 82,311K Shares Outstanding. Currently, annual sales are 377,710 K while annual income is -132,530 K. The company’s previous quarter sales were 11,770 K while its latest quarter income was -91,050 K.
